CMPD101 - CAS 865608-11-3
Catalog number: 865608-11-3
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C24H21F3N6O
Molecular Weight:
466.46
COA:
Inquire
Targets:
Others
Description:
CMPD101 is a selective GRK2/3 inhibitor with IC50 value is 54 nM for GRK3 and 32 nM for GRK2. It shows selectivity for GRK2/3 over GRK1/5. It can also reduce DAMGO-induced desensitization and internalization of μ-opioid receptors.
Purity:
98%
Appearance:
Off White solid
Synonyms:
3-[[[4-Methyl-5-(4-pyridinyl)-4H-1,2,4-triazol-3-yl]methyl]amino]-N-[[2-(trifluoromethyl)phenyl]methyl]benzamide
Solubility:
Soluble in DMSO
Storage:
-20℃ Freezer
MSDS:
Inquire
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Milligrams-Grams
InChIKey:
WFOVEDJTASPCIR-UHFFFAOYSA-N
InChI:
InChI=1S/C24H21F3N6O/c1-33-21(31-32-22(33)16-9-11-28-12-10-16)15-29-19-7-4-6-17(13-19)23(34)30-14-18-5-2-3-8-20(18)24(25,26)27/h2-13,29H,14-15H2,1H3,(H,30,34)
Canonical SMILES:
CN1C(=NN=C1C2=CC=NC=C2)CNC3=CC=CC(=C3)C(=O)NCC4=CC=CC=C4C(F)(F)F
1.Inhibition of prostatic smooth muscle contraction by the inhibitor of G protein-coupled receptor kinase 2/3, CMPD101.
Yu Q;Gratzke C;Wang Y;Herlemann A;Strittmatter F;Rutz B;Stief CG;Hennenberg M Eur J Pharmacol. 2018 Jul 15;831:9-19. doi: 10.1016/j.ejphar.2018.04.022. Epub 2018 Apr 23.
Alpha1-adrenoceptors induce prostate smooth muscle contraction, and hold a prominent role for pathophysiology and therapy of lower urinary tract symptoms in benign prostatic hyperplasia. G protein-coupled receptors are regulated by posttranslational regulation, including phosphorylation by G protein-coupled receptor kinases 2 and 3 (GRK2/3). Although posttranslational adrenoceptor regulation has been recently suggested to occur in the prostate, this is still marginally understood. With the newly developed CMPD101, a small molecule inhibitor with assumed specificity for GRK2/3 is now available. Here, we studied effects of CMPD101 on smooth muscle contraction of human prostate tissue. Electric field stimulation caused frequency-dependent contractions, which were inhibited concentration-dependently by CMPD101 (5 µM, 50 µM). 50 µM of CMPD101 did not affect myosin light chain (MCL) phosphorylation or Rho kinase activity, and did not alter contractions induced by highmolar KCl. Noradrenaline, the α;1;-adrenoceptor agonist phenylephrine, endothelin-1, and the thromboxane A;2; analogue U46619 induced concentration-dependent contractions, which were inhibited by CMPD101 (50 µM). CMPD101 (50 µM) did not change phosphorylation of β;2;-adrenoceptors or β;2;-adrenergic relaxation of prostate strips.
2.Role of G Protein-Coupled Receptor Kinases 2 and 3 in μ-Opioid Receptor Desensitization and Internalization.
Lowe JD;Sanderson HS;Cooke AE;Ostovar M;Tsisanova E;Withey SL;Chavkin C;Husbands SM;Kelly E;Henderson G;Bailey CP Mol Pharmacol. 2015 Aug;88(2):347-56. doi: 10.1124/mol.115.098293. Epub 2015 May 26.
There is ongoing debate about the role of G protein-coupled receptor kinases (GRKs) in agonist-induced desensitization of the μ-opioid receptor (MOPr) in brain neurons. In the present paper, we have used a novel membrane-permeable, small-molecule inhibitor of GRK2 and GRK3, Takeda compound 101 (Cmpd101; 3-[[[4-methyl-5-(4-pyridyl)-4H-1,2,4-triazole-3-yl] methyl] amino]-N-[2-(trifuoromethyl) benzyl] benzamidehydrochloride), to study the involvement of GRK2/3 in acute agonist-induced MOPr desensitization. We observed that Cmpd101 inhibits the desensitization of the G protein-activated inwardly-rectifying potassium current evoked by receptor-saturating concentrations of methionine-enkephalin (Met-Enk), [d-Ala(2), N-MePhe(4), Gly-ol(5)]-enkephalin (DAMGO), endomorphin-2, and morphine in rat and mouse locus coeruleus (LC) neurons. In LC neurons from GRK3 knockout mice, Met-Enk-induced desensitization was unaffected, implying a role for GRK2 in MOPr desensitization. Quantitative analysis of the loss of functional MOPrs following acute agonist exposure revealed that Cmpd101 only partially reversed MOPr desensitization. Inhibition of extracellular signal-regulated kinase 1/2, protein kinase C, c-Jun N-terminal kinase, or GRK5 did not inhibit the Cmpd101-insensitive component of desensitization.
3.Small-Molecule G Protein-Coupled Receptor Kinase Inhibitors Attenuate G Protein-Coupled Receptor Kinase 2-Mediated Desensitization of Vasoconstrictor-Induced Arterial Contractions.
Rainbow RD;Brennan S;Jackson R;Beech AJ;Bengreed A;Waldschmidt HV;Tesmer JJG;Challiss RAJ;Willets JM Mol Pharmacol. 2018 Sep;94(3):1079-1091. doi: 10.1124/mol.118.112524. Epub 2018 Jul 6.
Vasoconstrictor-driven G protein-coupled receptor (GPCR)/phospholipase C (PLC) signaling increases intracellular Ca;2+; concentration to mediate arterial contraction. To counteract vasoconstrictor-induced contraction, GPCR/PLC signaling can be desensitized by G protein-coupled receptor kinases (GRKs), with GRK2 playing a predominant role in isolated arterial smooth muscle cells. In this study, we use an array of GRK2 inhibitors to assess their effects on the desensitization of UTP and angiotensin II (AngII)-mediated arterial contractions. The effects of GRK2 inhibitors on the desensitization of UTP- or AngII-stimulated mesenteric third-order arterial contractions, and PLC activity in isolated mesenteric smooth muscle cells (MSMC), were determined using wire myography and Ca;2+; imaging, respectively. Applying a stimulation protocol to cause receptor desensitization resulted in reductions in UTP- and AngII-stimulated arterial contractions. Preincubation with the GRK2 inhibitor paroxetine almost completely prevented desensitization of UTP- and attenuated desensitization of AngII-stimulated arterial contractions. In contrast, fluoxetine was ineffective. Preincubation with alternative GRK2 inhibitors (Takeda compound 101 or CCG224063) also attenuated the desensitization of UTP-mediated arterial contractile responses.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 75-80-9 Tribromoethanol

Tribromoethanol
(CAS: 75-80-9)

Tribromoethanol is a sedative. It is used to anesthetize laboratory animals, particularly rodents, prior to surgery. It has the brand name Avertin as a solution...

CP74725 sodium salt
(CAS: 111477-48-6)

CP74725 sodium salt is a bio-active chemical compound.

CP-74667
(CAS: 108461-05-8)

CP-74667 is a new fluoroquinolone compound. It has good activity against several gram-positive and gram-negative pathogens.

CAS 4205-90-7 Clonidine

Clonidine
(CAS: 4205-90-7)

Clonidine is an α2-Adrenergic agonist for neuropathic pain.

CAS 147591-46-6 ID-8

ID-8
(CAS: 147591-46-6)

ID-8 is a DYRK inhibitor, and sustains embryonic stem cell self-renewal in long-term culture.

CAS 138736-73-9 HAMNO

HAMNO
(CAS: 138736-73-9)

HAMNO is a novel protein interaction inhibitor of replication protein A (RPA), which is involved in the ATR/Chk1 pathway. HAMNO acts by binding to the N-termina...

CAS 33342-05-1 Gliquidone

Gliquidone
(CAS: 33342-05-1)

Gliquidone is an ATP-sensitive K+ channel antagonist with IC50 of 27.2 nM.

CAS 69698-54-0 VIP(6-28)(human, rat, porcine, bovine)

VIP(6-28)(human, rat, porcine, bovine)
(CAS: 69698-54-0)

An effective antagonist of the actions of exogenous vasoactive intestinal peptide (VIP) on cAMP.

CAS 6106-07-6 L-Thyroxine sodium salt pentahydrate

L-Thyroxine sodium salt pentahydrate
(CAS: 6106-07-6)

L-Thyroxine sodium salt pentahydrate is an iodine containing hormone produced from thyroglobulin in the thyroid follicular cells. It reduces total cholesterol l...

CAS 62340-29-8 Oxyntomodulin (porcine, bovine)

Oxyntomodulin (porcine, bovine)
(CAS: 62340-29-8)

Oxyntomodulin is a naturally peptide hormone found in the colon, produced by the oxyntic (fundic) cells of the oxyntic (fundic) mucosa. It has been found to sup...

FR-186054
(CAS: 179053-90-8)

FR-186054, a pyridine derivative, has been found to be a sterol O-acyltransferase inhibitor and was once studied in hyperlipidaemia.

CAS 1223397-11-2 WZB 117

WZB 117
(CAS: 1223397-11-2)

WZB 117 is a GLUT inhibitor (Ki(app) = 0.2, 10 and 10 μM for GLUT4, GLUT1 and GLUT3, respectively) that inhibits passive glucose transport in human erythrocytes...

CAS 105956-99-8 Clinafloxacin hydrochloride

Clinafloxacin hydrochloride
(CAS: 105956-99-8)

Clinafloxacin hydrochloride is a novel fluoroquinolone antimicrobial agent as a potent intraphagocytic bactericidal agent. It displays broad-spectrum antibacter...

CAS 4940-39-0 Chromocarb

Chromocarb
(CAS: 4940-39-0)

Chromocarb is a vasoprotectant.

MK 0434
(CAS: 134067-56-4)

MK 0434 is a Cholestenone 5-alpha reductase inhibitor originated by Merck & Co and it is associated with a significant reduction in dihydrotestosterone. No deve...

CAS 412938-75-1 Neuropeptide S (Rat)

Neuropeptide S (Rat)
(CAS: 412938-75-1)

Neuropeptide S, a neuropeptide that plays a major role in regulating sleep and stress, is a potent endogenous neuropeptide S receptor (NSPR) agonist (EC50 = 3.2...

CAS 170787-99-2 Efaproxiral Sodium

Efaproxiral Sodium
(CAS: 170787-99-2)

Efaproxiral, a synthetic allosteric modifier of hemoglobinoxygen binding affinity, has been shown to bind reversibly to hemoglobin, stabilizing the deoxyhemoglobi...

CAS 491-54-3 Kaempferide

Kaempferide
(CAS: 491-54-3)

Kaempferide is an O-methylated flavonol. It can be found in Kaempferia galanga (aromatic ginger). The enzyme kaempferol 4'-O-methyltransferase uses S-adenosyl-L...

CAS 14919-37-0 (±)-Lauroylcarnitine chloride

(±)-Lauroylcarnitine chloride
(CAS: 14919-37-0)

(±)-Lauroylcarnitine chloride is an acylcarnitine used to improve in vivo absorption of certain hydrophilic compounds.

CAS 334-49-6 (E)-2-Decenoic acid

(E)-2-Decenoic acid
(CAS: 334-49-6)

trans-2-Decenoic Acid is isolated along with 10-hydroxy-trans-2-decenoic acid, a fatty acid unique to royal jelly.(E)-2-decanoic acid(trans-2-Decenoic Acid) and...

Quick Inquiry

Verification code

Featured Items